Marian Major
Overview
Explore the profile of Marian Major including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Kachko A, Selvaraj P, Rotstein D, Stauft C, Rajasagi N, et al.
NPJ Vaccines
. 2025 Feb;
10(1):30.
PMID: 39948345
Vaccines against SARS-CoV-2 have targeted the spike protein and have been successful at preventing disease. However, with the emergence of variants, spike-specific vaccines become less effective. The nucleocapsid protein is...
2.
Mackesy-Amiti M, Gutfraind A, Tatara E, Collier N, Cotler S, Page K, et al.
PNAS Nexus
. 2025 Jan;
4(1):pgae564.
PMID: 39777292
Global elimination of chronic hepatitis C (CHC) remains difficult without an effective vaccine. Since injection drug use is the leading cause of hepatitis C virus (HCV) transmission in Western Europe...
3.
Shi Z, Mhlanga A, Ishida Y, Josephson A, Collier N, Abe-Chayama H, et al.
Sci Rep
. 2024 Dec;
14(1):31826.
PMID: 39738554
Designing and carrying out a controlled human infection (CHI) model for hepatitis C virus (HCV) is critical for vaccine development. However, key considerations for a CHI model protocol include understanding...
4.
Jackson J, Kaldhone P, Stewart C, Anderson J, MacGregor S, Maclean M, et al.
Sci Rep
. 2024 Dec;
14(1):31540.
PMID: 39733162
Added safety measures coupled with the development and use of pathogen reduction technologies (PRT) significantly reduces the risk of transfusion-transmitted infections (TTIs) from blood products. Current approved PRTs utilize chemical...
5.
Kachko A, Selvaraj P, Liu S, Kim J, Rotstein D, Stauft C, et al.
Vaccine
. 2023 Dec;
42(3):608-619.
PMID: 38142216
In this study, we evaluated the immunogenicity and protective immunity of in vitro transcribed Venezuelan equine encephalitis virus (VEEV TC-83 strain) self-amplifying RNA (saRNA) encoding the SARS-CoV-2 spike (S) protein...
6.
Lee M, Major M, Hong H
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835186
Since November 2021, Omicron has been the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant that causes the coronavirus disease 2019 (COVID-19) and has continuously impacted human health. Omicron...
7.
Zubkova I, Zhao Y, Cui Q, Kachko A, Gimie Y, Chabot S, et al.
Vaccine
. 2022 Dec;
41(4):955-964.
PMID: 36586740
Introduction: A hepatitis B vaccination (HepB) series with an initial dose of hepatitis B immune globulin (HBIG) is the recommended prophylaxis for infants born to mothers with chronic hepatitis B...
8.
Salas J, Urbanowicz R, Guest J, Frumento N, Figueroa A, Clark K, et al.
Gastroenterology
. 2021 Oct;
162(2):562-574.
PMID: 34655573
Background & Aims: Development of a prophylactic hepatitis C virus (HCV) vaccine will require accurate and reproducible measurement of neutralizing breadth of vaccine-induced antibodies. Currently available HCV panels may not...
9.
Tatara E, Collier N, Ozik J, Gutfraind A, Cotler S, Dahari H, et al.
Proc Winter Simul Conf
. 2020 Jul;
2019:1008-1019.
PMID: 32624641
Hepatitis C (HCV) is a leading cause of chronic liver disease and mortality worldwide and persons who inject drugs (PWID) are at the highest risk for acquiring and transmitting HCV...
10.
Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, et al.
Vaccine
. 2019 Apr;
37(19):2608-2616.
PMID: 30962092
Background And Aims: Persons who inject drugs (PWID) are at highest risk for acquiring and transmitting hepatitis C (HCV) infection. The recent availability of oral direct-acting antiviral (DAA) therapy with...